drugset / Trial / NCT03513016

A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee

NCT03513016 ↗

Phase 1 Completed 78 enrolled Unity Biotechnology, Inc.
RandomizedSequentialDouble-blindTreatment

Summary

A study to evaluate safety, tolerability, and pharmacokinetics of a single intra-articular injection of UBX0101 in patients diagnosed with painful osteoarthritis of the knee.

Timeline

Start
2018-05-16
Primary completion
2019-03-29
Completion
2019-04-12

Drugs

EvaluationDrugModalityDoseRoute
Subject UBX0101 Unknown — Other

Indications